Department of Orthopedics, Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Suzhou, 215004, China.
Department of Orthopedics, Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Suzhou, 215004, China.
J Ethnopharmacol. 2024 Nov 15;334:118531. doi: 10.1016/j.jep.2024.118531. Epub 2024 Jul 5.
Ginseng (Panax ginseng C. A. Mey) is a common traditional Chinese medicine used for anti-inflammation, anti-apoptosis, anti-oxidative stress, and neuroprotection. Ginsenosides Rg1, the main active components isolated from ginseng, may be a feasible therapy for spinal cord injury (SCI).
SCI causes endothelial cell death and blood vessel rupture, ultimately resulting in long-term neurological impairment. As a result, encouraging spinal angiogenesis may be a feasible therapy for SCI. This investigation aimed to validate the capacity of ginsenoside Rg1 in stimulating angiogenesis within the spinal cord.
Rats with SCI were injected intraperitoneally with ginsenoside Rg1. The effectiveness of ginsenoside Rg1 was assessed using the motor function score and the motor-evoked potential (MEP). Immunofluorescence techniques were applied to identify the spinal cord's angiogenesis. Angiogenic factors were examined through Western Blot (WB) and Immunohistochemistry. Oxygen-glucose deprivation (OGD) was employed to establish the hypoxia-ischemia model in vitro, and astrocytes (As) were given ginsenoside Rg1 and co-cultured with spinal cord microvascular endothelial cells (SCMECs). Immunofluorescence, wound healing test, and tube formation assay were used to identify the co-cultured SCMECs' activity. Finally, network pharmacology analysis and siRNA transfection were applied to verify the mechanism of ginsenoside Rg1 promoting angiogenesis.
The rats with SCI treated with ginsenoside Rg1 indicated more significant functional recovery, more pronounced angiogenesis, and higher levels of angiogenic factor expression. In vitro, the co-culture system with ginsenoside Rg1 intervention improved SCMECs' capacity for proliferating, migrating, and forming tubes, possibly by promoting the expression of vascular endothelial growth factor (VEGF) in As via the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway.
Ginsenoside Rg1 can regulate As to promote angiogenesis, which may help to understand the mechanism of promoting SCI recovery.
人参（Panax ginseng C. A. Mey）是一种常用的传统中药，用于抗炎、抗细胞凋亡、抗氧化应激和神经保护。从人参中分离出的主要活性成分人参皂苷 Rg1 可能是脊髓损伤（SCI）的可行治疗方法。
SCI 导致内皮细胞死亡和血管破裂，最终导致长期神经功能障碍。因此，促进脊髓血管生成可能是 SCI 的一种可行治疗方法。本研究旨在验证人参皂苷 Rg1 刺激脊髓内血管生成的能力。
SCI 大鼠腹腔内注射人参皂苷 Rg1。通过运动功能评分和运动诱发电位（MEP）评估人参皂苷 Rg1 的效果。免疫荧光技术用于鉴定脊髓的血管生成。通过 Western Blot（WB）和免疫组织化学检测血管生成因子。采用氧葡萄糖剥夺（OGD）建立体外缺氧缺血模型，给予星形胶质细胞（As）人参皂苷 Rg1 并与脊髓微血管内皮细胞（SCMECs）共培养。免疫荧光、划痕愈合试验和管形成试验用于鉴定共培养 SCMECs 的活性。最后，通过网络药理学分析和 siRNA 转染验证人参皂苷 Rg1 促进血管生成的机制。
SCI 大鼠用人参皂苷 Rg1 治疗后功能恢复更明显，血管生成更明显，血管生成因子表达水平更高。在体外，用人参皂苷 Rg1 干预的共培养系统可改善 SCMECs 的增殖、迁移和形成管腔的能力，可能是通过 JAK2/STAT3 信号通路促进 As 中血管内皮生长因子（VEGF）的表达。
人参皂苷 Rg1 可以调节 As 促进血管生成，这有助于理解促进 SCI 恢复的机制。
Zotero 插件